178 related articles for article (PubMed ID: 21917962)
21. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
22. Fusion of the upstream vpu sequences to the env of simian human immunodeficiency virus (SHIV(KU-1bMC33)) results in the synthesis of two envelope precursor proteins, increased numbers of virus particles associated with the cell surface and is pathogenic for pig-tailed macaques.
Hout DR; Gomez ML; Pacyniak E; Mulcahy ER; Gomez LM; Jackson M; Flick M; Fegley B; McCormick C; Wisdom BJ; Culley N; Pinson DM; Powers M; Wong SW; Stephens EB
Virology; 2004 May; 323(1):91-107. PubMed ID: 15165822
[TBL] [Abstract][Full Text] [Related]
23. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
[TBL] [Abstract][Full Text] [Related]
24. Two distinct mechanisms regulate recruitment of murine leukemia virus envelope protein to retroviral assembly sites.
Lucas TM; Lyddon TD; Grosse SA; Johnson MC
Virology; 2010 Sep; 405(2):548-55. PubMed ID: 20655565
[TBL] [Abstract][Full Text] [Related]
25. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.
Bour S; Strebel K
J Virol; 1996 Dec; 70(12):8285-300. PubMed ID: 8970948
[TBL] [Abstract][Full Text] [Related]
26. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
27. Sequence Determinants in Gammaretroviral Env Cytoplasmic Tails Dictate Virus-Specific Pseudotyping Compatibility.
Song YE; Olinger GY; Janaka SK; Johnson MC
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894464
[TBL] [Abstract][Full Text] [Related]
28. A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent.
Oliveira NM; Trikha R; McKnight Á
Retrovirology; 2010 Oct; 7():81. PubMed ID: 20929586
[TBL] [Abstract][Full Text] [Related]
29. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
32. The receptors for gibbon ape leukemia virus and amphotropic murine leukemia virus are not downregulated in productively infected cells.
Liu M; Eiden MV
Retrovirology; 2011 Jul; 8():53. PubMed ID: 21729311
[TBL] [Abstract][Full Text] [Related]
33. Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections.
Tailor CS; Takeuchi Y; O'Hara B; Johann SV; Weiss RA; Collins MK
J Virol; 1993 Nov; 67(11):6737-41. PubMed ID: 8411376
[TBL] [Abstract][Full Text] [Related]
34. Vpu-mediated proteolysis of gp160/CD4 chimeric envelope glycoproteins in the endoplasmic reticulum: requirement of both the anchor and cytoplasmic domains of CD4.
Raja NU; Vincent MJ; abdul Jabbar M
Virology; 1994 Oct; 204(1):357-66. PubMed ID: 8091666
[TBL] [Abstract][Full Text] [Related]
35. Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function.
Geraghty RJ; Panganiban AT
J Virol; 1993 Jul; 67(7):4190-4. PubMed ID: 8510220
[TBL] [Abstract][Full Text] [Related]
36. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
37. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
38. Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.
Lukhele S; Cohen ÉA
Retrovirology; 2017 Mar; 14(1):18. PubMed ID: 28288652
[TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus-1 BF intersubtype recombinant viral protein U second α helix plays an important role in viral release and BST-2 degradation.
De Candia C; Espada C; Duette G; Salomón H; Carobene M
J Gen Virol; 2013 Apr; 94(Pt 4):758-766. PubMed ID: 23223624
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of retroviral vectors based on the gibbon ape leukemia virus.
Eglitis MA; Schneiderman RD; Rice PM; Eiden MV
Gene Ther; 1995 Sep; 2(7):486-92. PubMed ID: 7584127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
